The US Food and Drug Administration (FDA) has approved rilpivirine and cabotegravir (Cabenuva) to 2-month dosing for adults living with HIV-1 infection. Cabenuva was first approved by the FDA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results